Wilson Sonsini Goodrich & Rosati represented Ping An Ventures in the transaction.
Tmunity, a private clinical-stage biotherapeutics company focused on delivering the full potential of next-generation T-cell immunotherapy, announced that it has completed a $100 million Series A round of financing led by Ping An Ventures.
The investment will be used to advance and expand the business and operational structure of Tmunity to support the rapid translation, development, and manufacture of its portfolio of novel T-cell based immunotherapies for cancer treatment.
Ping An Ventures is the direct investment arm under Ping An Insurance (Group) Company of China, Ltd., one of the largest and most valuable financial service conglomerates in the world, ranked No. 39 on the Global Fortune 500. Ping An Ventures invests in healthcare industry in all stages with a specific focus on both growth-stage and PIPE investment. With multi-billion dollars asset under management in multiple funds, the investment team has invested in over 50 companies globally, covering all sectors in healthcare: Biotech, Diagnostics, Medical Device, Services, Healthcare and IT.
The WSGR team representing Ping An Ventures in the transaction was led by partners Karen Wong (Picture), Barry Taylor, and James Huie, and associates Michael Frank, Ivan Au, and Yingting Zhang.
Involved fees earner: Barry Taylor – Wilson Sonsini Goodrich & Rosati; James Huie – Wilson Sonsini Goodrich & Rosati; Ivan Au – Wilson Sonsini Goodrich & Rosati; Yingting Zhang – Wilson Sonsini Goodrich & Rosati; Karen Wong – Wilson Sonsini Goodrich & Rosati; Michael Frank – Wilson Sonsini Goodrich & Rosati;
Law Firms: Wilson Sonsini Goodrich & Rosati;
Clients: Ping An Ventures ;